The latest

News

Latest news126

A large pile of empty yellow barrels with radioactivity warning labels.

First Drug Trial in US for Pill To Guard Against Nuclear Accidents

HOPO 14-1 is an investigative drug that is hoped can protect and treat victims of nuclear fallout, by binding (or chelating) contaminated heavy metals and removing them from the body. It is thought to be effective against Uranium and other materials used in nuclear weapons, such as dirty bombs or ballistic missiles. Read post
Katy Digovich

“Can I Cure My Diabetes With Stem Cells?” Katy Digovich Delivers TED Talk

CEO Katy Digovich recently gave a passionate TED Talk about her motivation for launching and leading Minutia. A former Princeton basketball player, Katy lives with diabetes. Working with the Clinton Global initiative in Africa, she learned that people with diabetes in the Third World face an early death sentence due to the cost of insulin monitoring and delivery. Minutia is developing cell therapy in the form of cells engineered with nanosensors to measure insulin levels and deliver dosage. Read post
The Regel Therapeutics leadership team

Tenant Spotlight on Regel Therapeutics: A New Approach to Gene Therapy

“I always used to enjoy science and technological innovation. For a scientist, curiosity leads to discovery, but it is a need that leads to invention. In the back of my mind, I always knew that to make a clinical product into a reality, I have to take the technology out of the lab and develop it in an industry setting. Patients and their caregivers motivated me to take this leap into entrepreneurship," says Navneet Matharu. Read post
Ray Therapeutics homepage with close-up of human face and eye

Ray Therapeutics: Anatomy Of A Biopharma VC Deal

Until 2010, leading a biotech wasn’t on Paul Bresge's radar. He’d built a long and successful career as a leader in unrelated industries -- industrial tools and a courier service, for example. Then, his 15-year-old daughter was diagnosed with retinitis pigmentosa, a rare genetic disease that causes degradation of retinal cells over time. She was going blind. Ophthalmologists told him there was nothing that could be done to save his daughter’s vision. Read post
View into the back of an ambulance responding to a call

Coagulant Therapeutics Announces Publication in Blood Advances Describing Novel Nanobody Library to Activated Protein C and Initial Leads for Treatment of Trauma and Hemophilia

By using assays specific for coagulation, inflammation and cell survival functions of APC, the investigators were able to identify an array of human APC specific antibodies able to retain or eliminate these functions. This represents a tool chest for APC targeted therapies that has already identified a lead candidate for the treatment of trauma and hemophilia. Read post
Schematic protein structure

Profluent Announces Launch With $9 Million Seed Round

Profluent is using deep generative models to ‘learn the language of biology’ in order to design new, functional proteins. The goal of protein design is to create novel or enhanced proteins with specific uses. These could include lasting cures for diseases that are free from patent restrictions or new enzymes that can break down unrecyclable plastics. Read post
Don Ganem and Kelly Wong

Tenant Spotlight on Via Nova Therapeutics & Antiviral Development: Seek Out Investors Whose Aims Align With Yours

“Don and I got to talking and we decided, let's try to get these assets out of Novartis and found Via Nova. A little over a year ago, we were able to execute on a Series A, to get an initial funding of $20 million, which also enabled the in-licensing of the assets from Novartis. The four that we chose are for influenza, human rhinovirus, BK polyomavirus and adenovirus.” Two scientists without a team or a lab raised $20 million? You heard right. That funding came from Aditum Bio, an investment firm founded by former Novartis scientists who could appreciate that millions of dollars had already been invested into the R&D for these assets. Read post